Cavosonstat
As of the edition of 20 October 2026, Cavosonstat is a small molecule: in active development; acts on ADH5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2015
- Kind
- Small molecule
- Registered trials
- 9, 0 stopped early
- Disease areas
- Lungs and airways; Digestive system; Inherited and neonatal; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADH5 | Alcohol dehydrogenase class-3 | P11766 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 4 | 2 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Vertex | Lead sponsor of trials | 2014 to now |
| GSNOR Therapeutics | Lead sponsor of trials | 2021 to now |